PROLIFERATIVE ACTIVITY IN SPITZ NEVI COMPARED WITH OTHER MELANOCYTIC SKIN-LESIONS

被引：7

作者：

HOFMANNWELLENHOF, R

RIEGER, E

SMOLLE, J

KERL, H

机构：

[1] Department of Dermatology, University of Graz Auenbruggerplatz

来源：

MELANOMA RESEARCH | 1993年 / 3卷 / 05期

关键词：

IMAGE ANALYSIS; PCNA; SPITZ NEVI;

D O I：

10.1097/00008390-199310000-00002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Proliferative activity has been shown to correlate with the degree of malignancy in various human neoplasms Immunostaining with the monoclonal antibody PC10 binding to proliferating cell nuclear antigen (PCNA) facilitates the assessment of proliferation in routinely fixed, paraffin-embedded tissue sections. In this study we investigated the expression of PCNA in 29 Spitz's naevi In comparison with 43 primary malignant melanomas (MM), 18 cutaneous metastases of malignant melanoma (MMM) and 16 benign melanocytic naevl (BMN). After selection al the microscopic field with the highest number of PCNA-positive nuclei, the nuclear density (ND(max)) of PCNA-stained nuclei in this field was assessed using interactive image analysis. The mean value of ND(max) (given as 1000 nuclei/mm3 tissue) of SN was 27.9 (+/-16.7) and differed significantly from that of MM (48.1 +/- 40.5; U-test: p<0.05) and that of MMM (114.4 +/- 56.3; p<0.01). Comparing ND(max) of the subgroups of MM according to their maximal vertical tumour thickness with ND(max) of SN we found significant differences only between SN and MM > 1.5 mm thick (n = 14; ND(max) = 67.8 +/- 36.1) but not between SN and MM less-than-or-equal-to 1.5 mm thick (n = 29; ND(max) = 38.8 +/- 39.3). PCNA expression in SN did not differ from that of BMN (ND(max) 23.8 +/- 28.5). Proliferative activity as assessed by measurement of PCNA expression therefore showed significant differences between BMN, SN and thin primary melanomas on one hand and thick primary melanomas and cutaneous metastases of malignant melanomas on the other hand.

引用

页码：313 / 317

页数：5

共 35 条

[1]

Spitz S., Melanoma of childhood, Am J Pathol, 24, pp. 591-609, (1948)

[2]

Tubiana M., Courdi A., Cell proliferation kinetics in human solid tumors: Relation to probability of metastatic dissemination and long-term survival, Radiother Oncol, 15, pp. 1-18, (1989)

[3]

Miyachi K., Fritzler M.J., Tan E.M., Autoantibodies to a Nuclear Antigen in Proliferating Cells. J Immunol, 121, pp. 2228-2234, (1978)

[4]

Bravo R., Frank R., Blundell P.A., Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta, Nature, 326, pp. 515-517, (1987)

[5]

Prelich G., Tan C.K., Kostura M., Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein, Nature, 326, pp. 517-520, (1987)

[6]

Kurki P., Vanderlaan M., Dolbeare F., Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle, Exp Cell Res, 166, pp. 209-219, (1986)

[7]

Dawson A.E., Norton J.A., Weinberg D.S., Comparative assessment of proliferation and DNA content in breast cancers by image analysis and flow cytometry, Am J Pathol, 36, pp. 1115-1124, (1990)

[8]

Robbins B.A., De La Vega D., Ogata K., Immuno-histochemical detection of proliferating cell antigen in solid human malignancies, Arch Pathol Hah Med, 111, pp. 841-845, (1987)

[9]

Yu C.C.-W., Hall P.A., Fletcher C., Haemangiocyto-mas: The prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA), Histopathology, 19, pp. 29-33, (1991)

[10]

Takahashi Y., Robinson W.A., Tan E.M., Proliferating cell nuclear antigen in blast crisis cells of patients with chronic myeloid leukaemia, J Natl Cancer Inst, 73, pp. 655-661, (1984)

← 1 2 3 4 →